PARP1 and esophageal squamous cell carcinoma: The combined effect of PARP1 polymorphism Val762Ala with other polymorphism have already be reported in different cancer such as lung cancer [43], noncardia gastric cancer [52], esophageal squamous cell carcinoma [36], skin cancer [53], breast cancer [32], colorectal cancer [39] and cancer [54].